RxDoctor Payments Data

Nicole Gill, DO

Neurology · Durham, NCNPI 1548491996

Payments from drug & device makers

$91,922in general payments, 2019–2025

Across 491 payments — averaging $187.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$32K
  • Amgen$23K
  • Teva Pharmaceuticals USA, Inc.$20K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Pfizer$5K
  • Biohaven Pharmaceutical Holding Company Ltd.$605
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$1,0001%
  • Speaking & faculty fees$77,55084%
  • Travel & lodging$2,9873%
  • Food & beverage$10,27811%
  • Education$1070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,922 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$33,219
Medicare patients
60
Services billed
3,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate44$52,865
UbrelvyUbrogepant33$36,782
QuliptaAtogepant22$33,041
Emgality PenGalcanezumab-Gnlm36$32,033
Aimovig AutoinjectorErenumab-Aooe30$22,250
Ajovy AutoinjectorFremanezumab-Vfrm16$19,211
ZavzpretZavegepant Hcl13$18,646
RizatriptanRizatriptan Benzoate38$756
Topiramate31$466
Naratriptan Hcl11$331
Ondansetron Hcl18$282
Gabapentin13$186
Lamotrigine14$153
Amitriptyline Hcl15$123
Sumatriptan Succinate17$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret$5,474$71,51157 claims
AbbVieUbrelvy, Qulipta$32,337$69,82255 claims
Upsher-smith Laboratories LLCTopiramate$261$46631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →